End-to-End Single-Site Solution from Drug Substances to Fill-Finish & Packaging
TOKYO, January 6, 2021― FUJIFILM Corporation (President: Kenji Sukeno) is making an investment of more than 200 Billion yen (2 Billion USD) to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business (CDMO).
Leading group purchasing organization chooses Fujifilm’s image and data integration solution for the operating room and interventional suites
Largest urology practice with 30+ locations and 90+ providers standardizes their practice with the Persona CT computed tomography system for advanced oncology treatment planning
Company announces development of new image processing technologies designed to enhance visualization during therapeutic procedures
Showcased at RSNA 2020, the new fluoroscopy systems are designed to deliver rapid access to high-resolution real-time imaging of moving body structures, while reducing patient dose
Unique technology to be showcased for Healthcare Providers at RSNA 2020
Lexington, Mass, & Bothell, Wash., November 19, 2020-- FUJIFILM Medical Systems U.S.A., Inc.
TOKYO, October 22, 2020—FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada) has announced that the company has partnered with Chinese pharmaceutical company Carelink Pharmaceutical Co., Ltd. (hereinafter “Carelink”) in deploying anti-influenza drug Avigan® Tablets (generic name: favipiravir,“Avigan”) in China. Going forward, through a future application and approval of Avigan for imported drug registration, to be submitted by Carelink, FUJIFILM Toyama Chemical aims to introduce Avigan to the Chinese market.
TOKYO, October 16, 2020—FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced that the company filed an Application for Partial Changes to manufacturing and marketing approval matters of its anti-influenza drug Avigan® Tablet (generic name: favipiravir,”Avigan”) to the Ministry of Health, Labour and Welfare in Japan. The filing seeks to add an indication and other items relating to novel coronavirus infections (hereinafter “COVID-19”).
Partnership aims to help more clinicians improve image quality and determine patient breast density
HILLERØD, Denmark, October 8, 2020 - FUJIFILM Diosynth Biotechnologies, a world leading Contract Development and Manufacturing Organization (CDMO) for biologics, viral vaccines and viral vectors, today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP1 facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator.
MILAN (Italy) and MADISON (Wis., USA)– Axxam S.p.A., a leading provider of integrated drug discovery services across life sciences industries, and FUJIFILM Cellular Dynamics, Inc., a leading developer and manufacturer of human induced pluripotent stem cell (hiPSC) models and therapies, announce a strategic alliance to improve the drug discovery process.
TOKYO, October 7, 2020 - FUJIFILM Corporation (President: Kenji Sukeno) is expanding its gene therapy offering, with the addition of viral vector process development and GMP1 manufacturing services at FUJIFILM Diosynth Biotechnologies’ in the North East of the United Kingdom (UK).
TOKYO, September 23, 2020—FUJIFILM Toyama Chemical Co., Ltd.
Program to Investigate the Role of Point-of-Care Ultrasound in the Intensive Care Unit
Bothell, WA – September 3, 2020— FUJIFILM Sonosite, Inc., specialists in developing cutting-edge point-of-care ultrasound (POCUS) solutions, and part of the larger
Virtual ground-breaking ceremony held as planned expansion work begins
COLLEGE STATION, Texas, August 19, 2020 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, held a virtual ground-breaking ceremony on August 19, 2020 to signal the start of its Advanced Therapies Innovation Center construction project. The $55M USD building is part of previously announced investments by FUJIFILM Corporation.
BILLINGHAM, UK, August 17,2020 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and
FUJIFILM Wako Diagnostics U.S.A. Corporation will become part of FUJIFILM Medical Systems U.S.A., Inc.
Gaithersburg, MD and Morrisville, NC, July 23, 2020
Bothell, WA, July 21, 2020 - FUJIFILM Sonosite, Inc., specialists in develo
System enables both flexible and rigid endoscopy to be performed using a single tower
Lexington, Mass., July 15, 2020 – Fujifilm announced today that as of October 1, 2020, FUJIFILM New Development U.S.A., Inc., an innovative provider of minimally invasive surgical systems, will merge with FUJIFILM Medical Systems U.S.A., Inc., a leading provider of endoscopic imaging solutions.
HERTFORDSHIRE, England, PITTSBURGH and TOKYO – Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie’s Humira® (adalimumab), for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis (4 years and older), psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations.
Three more recipients awarded funding assistance to pursue translational medicine research at Harvard Medical School
Industry leaders to research the growing importance of point-of-care ultrasound in COVID-19 care
Licensing agreement was signed on the development, manufacture and sales of anti-influenza virus drug Avigan® Tablets
CAMBRIDGE, Mass., June 9, 2020 – FUJIFILM Pharmaceuticals U.S.A., Inc. a wholly owned U.S.
- Doubling the drug substance production capacity
Fabian to serve as Vice Chair of the Board
FUJIFILM Wako Automation Corporation, announced today that it will provide free image analysis services to help scientists and researchers rapidly and accurately analyze imaging data that may lead to the next breakthrough on COVID-19.
Delaney Radiology, Banner Imaging, Radiology Consultants industry-leading workflow management solution
Company commences joint research study with leading medical institutions in Japan, applying lesion quantification technology for pneumonia
Fabian, President and COO of FUJIFILM Sonosite, Inc., applauds AdvaMed for its leadership in times of health crisis
Company adds artificial intelligence, high-tech image capture, and advanced data processing to further accelerate innovations for its wo
LEXINGTON, Mass., May 14, 2020 - FUJIFILM Medical Systems U.S.A., Inc., a leading provider of Enter
Company’s ELUXEO and EB-530US selected by largest member-driven healthcare GPO in the country
HILLERØD, Denmark, April 30, 2020 – FUJIFILM Diosynth Biotechnologies, a world leading biologics-Contract Development and Manufacturing Organization (CDMO), today announced that it will reserve manufacturing capacity for a future COVID-19 therapy for the COVID-19 Therapeutics Accelerator.
Lexington, Mass. – April 30, 2020— FUJIFILM Medical Systems, U.S.A., Inc.
FUJIFILM Europe GmbH will launch a new software version with a new function for colon polyp characterisation utilising a type of Artificial Intelligence (AI) called deep le
Capabilities expand to supplying plasmids for triple transfections
TOKYO, April 15, 2020 ― FUJIFILM Corporation (President: Kenji Sukeno) has announced that it has expanded its manufacturing capacity at FUJIFILM Toyama Chemical Co., Ltd.
TOKYO, April 9, 2020 ― FUJIFILM Corporation (President: Kenji Sukeno) announces the initiation of a U.S.
FUJIFILM Irvine Scientific creates the FUJIFILM “Discovery Research” organization to enable speedy, efficient delivery of FUJIFILM Cellular Dynamics iPSC-derived products through their worldwide distribution channels
Enters partnership agreement with Precision NanoSystems Inc.
The expansion will take place in its Billingham, UK site
MORRISVILLE, NC, March 16, 2020 - FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of th
Groundbreaking Ceremony held as work for the BioCampus development commences
Steve Bagshaw to retire as CEO; Executive Committee appoints Martin Meeson, President & COO, FUJIFILM Diosynth Biotechnologies U.S.A as new Chief Executive Officer
MADISON, Wis., March 2, 2019 — FUJIFILM Cellular Dynamics, Inc. (FCDI), a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, will begin operation of its new cGMP-compliant*1 iPSC production facility on March 4.
Capacity increase will support production of high throughput and large volume gene therapy products
FUJIFILM AND SUN NUCLEAR JOIN EFFORTS TO RAISE AWARENESS OF BREAST CANCER
MORRISVILLE, N.C., February 25, 2020 – FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Patented, industry leading Synapse VNA outranks competitive solutions
Industry leader to present the market with a one-stop, single-vendor solution for medical image capture, management, storage, and image enablement
FUJIFILM Holdings Corporation (President: Kenji Sukeno) is proud to announce that the company has achieved a place on the “CDP*1 Climate Change A List,” winning the highest level of recognition awarded to companies for their efforts against climate change.
For Patients with Mild Cognitive Impairment and Mild Alzheimer Disease
Tokyo, December 18, 2019 — FUJIFILM Corporation (President: Kenji Sukeno) (“Fujifilm”) today announced that it has entered into an agreement with Hitachi, Ltd. (President & CEO: Toshiaki Higashihara) (“Hitachi”) to acquire Hitachi’s Diagnostic Imaging-related Business (the “Business”) to further expand its Healthcare business. Prior to the acquisition, Hitachi will establish a company (the “New Company”) and implement an absorption-type company split whereby the New Company will absorb the Business.
Lexington, Mass., Dec.
Tokyo, December 9, 2019 ―
Strengthening fundamental research capabilities in the areas of gene therapy, cell therapy and regenerative medicine applications,
Healthiest 100™ recognizes FUJIFILM Diosynth Biotechnologies as a top ten healthiest employer in nation
Morrisville, North Carolina, November 25, 2019 - FUJIFILM Diosynth Biotechnologies (FDB), a leading global biologics and gene therapy Contract Development and Manufacturing Organization (CDMO) has announced its participation as a founding member in a newly announced center for innovation an
Company to debut convergence of cardiology, radiology, mammography, and 3D imaging in common platform with Synapse 7x
Series of educational workshops designed to educate radiologists, administrators, technologists on the potential benefits of the latest breast cancer screening technology
Forward-thinking design eliminates traditional glass substrate from the capture layer, the most fragile layer inside.
Forward-thinking design eliminates traditional glass substrate from the capture layer, the most fragile layer inside.
Continues expansion of enhanced imaging technology solutions designed for hospitals and outpatient applications at RSNA
Latest advancements in Artificial Intelligence research can potentially help healthcare providers impact patient care and improve workflows in the ER, OR and General X-ray
BOTHELL, WA, November 21, 2019 (Booth #4111) – FUJIFILM SonoS
Clinical Development of a Novel Liposome Drug with Mechanism of Selective Delivery of Anti-Cancer
CAPITAL INVESTMENT TOTALING APPROXIMATELY 13 BILLION YEN COMMITTED TO EXPAND GENE THERAPY CAPABILITIES
FUJIFILM Diosynth Biotechnologies receives top honors in Triangle Business Journal’s 2019 Healthiest Employers Awards
TORONTO, CANADA, October 31, 2019 – FUJIFILM VisualSonics Inc., a world leader in ultra-high frequency ultrasound and photoacoustic imaging systems and subsidiary of FUJIFILM SonoSite, Inc., and part of the Fujifilm Healthcare portfolio, celebrated twenty years of innovation in scientific research on October 29, 2019. To mark the special occasion, FUJIFILM VisualSonics hosted an open house at their Toronto based office and welcomed guests to participate in product demonstrations as well as a display showcasing the evolution of ultra-high frequency ultrasound and photoacoustic technology.
Company demonstrates various educational and training solutions designed specifically for point-of-care ultrasound to more than 8,000 emergency medicine professionals
Company to support multiple educational opportunities for clinicians during conference
Lexington, MA, October 24, 2019 (Booth #502) – FUJIFILM Medical Systems U.S.A., Inc.- Endoscopy, a division of the Fujifilm Healthcare portfolio, will unveil eight new endoscopes as well as exhibit its comprehensive suite of endoscopic imaging solutions at the American College of Gastroenterology’s Annual Meeting (ACG). The event takes place from October 27-29, 2019 at the Henry B. Gonzalez Convention Center in San Antonio, TX.
Company demonstrates suite of imaging and educational solutions to more than 14,000 anesthesia professionals
BOTHELL, WA, October 17, 2019 - FUJIFILM SonoSite, Inc., specialists in developing cutting-edge, point-of-care ultrasound solutions, and part of the greater Fujifilm Healthcare portfolio, has entered into an agreement with Intelligent Ultrasound Group, a global, world-class ultrasound software and simulation developer, allowing the companies to deliver a training solution to the point-of-care ultrasound (POCUS) market.
Industry leader presents two new pulmonary imaging devices
Innovative ART products now available in Europe
Campaign reflects diverse portfolio and celebrates advancements from 85 years of experience designed to improve quality of life for people worldwide
Health system installs Synapse VNA and Synapse Mobility Enterprise Viewer
Company expands interventional and core GI endoscopy portfolio
Multi-lingual POCUS educational tools are the result of global member demand
AI2 Incubator delivers deep learning and computer vision technology on limited hardware capacity to enable new levels of ultrasound detection
First-of-kind solution now in clinical use at North Memorial Health
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function
SANTA ANA, California, 10 September, 2019: FUJIFILM Irvine Scientific, Inc., a world leader in the optimization, development and manufacture of cell culture media and industrial cell culture solutions, today introduced BalanCD Gal Supplement. The new formula has been developed to increase galactosylation in biotherapeutic development, to help achieve desired glycan profiles for improved product quality and antibody efficacy.
Tokyo, August 1, 2019 ‒ FUJIFILM Corporation (“Fujifilm”) today announced that it has completed the acquisition of Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark (“Hillerød Manufacturing”) from Biogen. Fujifilm invested approximately US$890 million in cash for the transaction.
LEXINGTON, Mass., August 1, 2019 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of Enterprise Imaging and Medical Informatics solutions, today announced that three additional healthcare facilities have integrated various solutions from the company’s Synapse® Enterprise Imaging portfolio into their IT infrastructure. The three facilities will implement offerings from the Synapse portfolio to improve workflows, enhance collaborative care and deliver better patient outcomes.
Collaboration to develop artificial intelligence (AI) enhanced ultrasound technology aimed at increasing the utility of ultrasound and improving our nation’s healthcare system
Established through a $1,000,000 gift from Fujifilm to Harvard Medical School, the program will advance education and research in the field of translational medicine.
Cambridge, Mass., July 29, 2019 – FUJIFILM Holdings America Corporation (Fujifilm), today announced the first-ever recipients of the Fujifilm Fellowship at Harvard Medical School (HMS).
Tokyo, July 25, 2019 ―
Fujifilm will showcase the new addition to its women’s health product portfolio at AHRA booth #1111
To enhance the Process of Research and Development of Drug Candidates
Lexington, Mass., July 10, 2019
New facility brings rapid, reliable delivery of cell culture media to European customers
LEXINGTON, MASS., July 1, 2019 — FUJIFILM New Development, U.S.A., Inc. (Fujifilm), an innovative provider of minimally invasive surgical solutions, is now an active supplier with
Lexington, Mass., July 1, 2019 – FUJIFILM Medical Systems U.S.A., Inc.,
• Incubated by Versant in partnership with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies
Company to Exhibit Enterprise Imaging Solution with Advanced Analysis & Monitoring; Best in Class Point-of-Care Ultrasound
Company to Exhibit Enterprise Imaging Solution with Advanced Analysis & Monitoring; Best in Class Point-of-Care Ultrasound
Company to showcase market leadership with comprehensive Synapse portfolio, robust AI capabilities, and #AskIndustry panel participation
Lexington, Mass., June 13, 2019
Lexington, Mass., June 12, 2019 – FUJIFILM Medical Systems U.S.A., Inc.,
LEXINGTON, Mass., June 11, 2019 –
Tokyo, June 5, 2019 ―FUJIFILM Corporation (President: Kenji Sukeno), today announced an initial $10M USD investment to establish a full scale, fully integrated continuous processi
Signs a service agreement on the development of regenerative medical products
for reducing the use of immunosuppressants
LEXINGTON, Mass., June 4, 2019– FUJIFILM Medical Systems U.S.A., Inc
Opening Reflects Commitment to Strategic Investments and
Collaborations with Life Sciences Community
Tokyo, May 28, 2019 ― FUJI
Tokyo, May 17, 2019 ― FUJIFILM
LEXINGTON, Mass., May 15, 2019
LEXINGTON, Mass., May 15, 2019 (Boot
Lexington, M.A., May 14, 2019 (Booth 4322)– FUJIFILM Medical Systems U.S.A., Inc., a leadi
The BioCampus will be partly supported by the Tees Valley Combined Authority
FUJIFILM Holdings joins the international initiative “RE100”
Mississauga, Ontario, April 11,
Valhalla, NY, March 28, 2019 (Booth #629) — Fujifilm will be pre
Valhalla, NY, March 28, 2019 —
New features will be on display this spring at the National Consortium of Breast Centers conference and the Society of Breast Imaging Symposium
SANTA ANA, California, March 12, 2019: FUJIFILM Irvine Scientific, Inc., a world leader in the optimization and manufacture of cell culture media, today announced
March 12, 2019
Wayne, N.J., February 19, 2019 – FUJIFILM Medical Systems U.S.A.
The initiative will be launched as the FDB Centre of Excellence in Bioprocessing 2.0
Increased digital X-ray installations across the U.S. are driven by Fujifilm’s new FDR Go PLUS, which began shipping in 2018.
January 15, 2019
TITRES ACHIEVED ARE IN EXCESS OF 10g/L WITHOUT COMPROMISING PRODUCT QUALITY
hiPSC-derived microglia are utilized with the aim of advancing research to fulfill unmet medical needs for patients with neurodegenerative diseases
INCREASING ITS BIOPHARMACEUTICAL PRODUCTION CAPACITY AND CAPABILITIES TO MEET THE GROWING NEEDS OF ITS CUSTOMER PORTFOLIO
Fujifilm is investing in the cGMP-compliant facility located in Madison, Wisconsin with the goal to begin operations by March 2020
Accelerating the growth of the cell culture media business
January 2, 2018
Wayne, N.J., Dec.
Billingham, United Kingdom, 6 December 2018 ‒ FUJIFILM Diosynth Biotechnologies (
Fujifilm’s comprehensive endoscopy portfolio now available to over 105,000 members through one of nation’s leading healthcare solutions organizations
Stamford, CT, November 24, 2018 (Booth #2545) –
Innovations include single exposure energy subtraction and next-generation X-ray room retrofit detectors
Company unveils two dedicated solutions designed to address imaging needs in the operating room (OR)
Successfully encapsulates anti-cancer agent in newly invented liposome
Drug release mechanism of continuous action in tumors
Stamford, Conn., November 7, 2018 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of Medical Informatics and Enterprise Imaging solutions, today announced that its Synapse 5 PACS has been granted a Risk Management Framework-based (RMF) Authority to Operate (ATO) on U.S. DoD networks. The U.S.
STAMFORD, Conn., October 29, 2018 – FUJIFILM Medical Systems U.S.A., Inc
Stamford, CT, October 24, 2018 – FUJIFILM Medical Systems U.S.A., Inc., a
BOTHELL, WA, October 23, 2018 – FUJIFILM SonoS
World’s first 85cm 64 and 128 slice wide bore CT unit for oncology
Valhalla, N.Y., Stamford, Conn., Bothell, WA – October 18, 2018– Booth #475 ‒FUJIFILM New Development, U.S.A., Inc.,
Unwavering commitment to achieving continued corporate growth
October 15, 2018
Company’s EBUS featured in Cook Medical Educational Sessions
BOTHELL, WA, October 1, 2018 – FUJIFILM SonoSite, Inc., specialists in developing cutting-edge, point-of-care ultrasound solutions, today announced its entry into the medical informatics space with the launch of a robustpoint-of-care workflow solution, SonoSite Synchronicity™. A new and exciting venture for the company, SonoSiteSynchronicity software is designed specifically for point-of-care ultrasound to streamline and standardize clinical workflow while delivering administrative efficiencies with flexible crede
A company for research, development, manufacture and sale of diagnostic and therapeutic drugs
- a new development center for the next generation of advanced AI technology enhances collaboration with academic institutions to resolve the issues facing society
September 27, 2018
HERTFORDSHIRE, England and PITTSBURGH
STAMFORD, Conn., September 11, 2018 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of Enterprise Imaging and Informatics solutions, is continuing its partnership with the American College of Radiology (ACR),
FUJIFILM Corporation (President: Kenji Sukeno) is proud to announce that its 3D image analysis system, “SYNAPSE VINCENT,” has won the “Red Dot Award: Communication Design 2018” in the “Red Dot” product design award program organized by Design Zentrum Nordrhein Westfalen based in Essen, G
- Development of Medical Imaging Diagnostic Support Systems Using Artificial Intelligence-
BOTHELL, WA, August 15, 2018 – FUJIFILM SonoSite Inc.
Takaaki Ueda appointed as Chairman and Chief Executive Officer and Rich Fabian promoted to President and Chief Operating Officer
HERTFORDSHIRE, England and PITTSBURGH
From battlefield to bedside, these rugged and reliable solutions have ushered in a new era of helping clinicians bring ultrasound to any patient, anywhere, anytime.
STAMFORD, Conn., July 19, 2018 (Booth 106)– FUJIFILM Medical Systems U.S.A., Inc
The first chemically-defined, animal component-free cell culture medium for natural killer (NK) cells
Fujifilm pediatric suite of digital radiography solutions is available through Vizient group purchasing contract
Stamford, CT, June 11, 2018 – FUJIFILM Medical Systems, U.S.A., Inc
FUJIFILM Cellular Dynamics, Inc., licenses University of California – Irvine’s technologies for derivation of microglia
June 4, 2018
Fujifilm to also showcase collaboration offerings at BIO International Convention (BIO) 2018 exhibition center June 5 – 7, 2018 at booth #863
May 25, 2018
COLLEGE STATION, Texas, May 23, 2018 ‒ FUJIFILM Diosynth Biotechnologies (Fujifilm)
Allendale, N.J., May 15, 2018 (Booth 415) – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of endoscopic imaging solutions, will connect with nearly 2,000 GI professionals at the Society of Gastroenterology Nurses and Associates (SGNA)
STAMFORD, Conn., May 15, 2018 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics solutions, today announced that it will showcase its comprehensive portfolio of pediatric solu
May 14, 2018
Clinical Development of Liposome Drug for Improvement of Pharmacological Efficacy through Selective Delivery of Anti-Cancer Agent to Tumors
May 9, 2018
Valhalla, N.Y.
TOKYO, Japan– April 11, 2018 – Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced the company will partner with Mylan N.V. (NASDAQ: MYL) to commercialize FKB327, a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics.
Clinical Trials to Be Conducted for a Novel Drug Approval
Fujifilm’s newest innovations in digital radiography delivers image quality, dose efficiency and improves patient safety.
Maximizing synergies and further expanding the bio-medical business
March 29, 2018
TORONTO, March 21, 2018 – FUJIFILM VisualSonics Inc.
3D image analysis system for medical use “SYNAPSE VINCENT”,
hybrid instant camera “instax SQUARE SQ10” and others
March 12, 2018
Toyama Chemical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo; President: Junji Okada), a FUJIFILM Company, has announced that it has started to enroll patients for phase III clinical study in Japan of the antiviral drug favipiravir for ixodid tick-borne infectious disease, serious fever with thrombocytopenia syndrome (SFTS).
The latest workstation will be on display this spring at the National Consortium of Breast Centers (NCoBC) conference and the Society of Breast Imaging (SBI) Symposium.
Stamford, CT, March 1, 2018 (Booth #6637)– FUJIFILM Medical Systems U.S.A., Inc.,
Patients in communities across the United States will reap the benefits of 3D mammography with new installations.
February 8, 2018
FUJIFILM Corporation
Takeda Pharmaceutical Company Limited
College Station, TX, U.S.A., January 24, 2018 ‒ FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience focused on the development and manufacture of recombinant biopharmaceuticals and Advanced Therapies, has announced the opening of it
The Company also revealed expansion of its Apollo™ Cell Line Development capabilities at its Billingham, U.K. Site
MORRISVILLE, N.C., Jan.
MADISON, Wis., Dec. 27, 2017— Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of human induced pluripotent stem cells (iPSCs) and differentiated tissue-specific iPSC-cells, announced that its iCell® Cardiomyocytes were launched into space via SpaceX’s 13th commercial resupply services mission to the International Space Station on Dec.15, 2017.
Allendale, N.J., December 11, 2017 (Booth #400) – FUJIFILM Medical Systems U.S.A. Inc.,- Endoscopy, will feature its endoscopic imaging solutions at the 41st Annual New York Course of the New York Society for Gastrointestinal Endoscopy (NYSGE). NYSGE will be held December 14-15 at the New York Marriott Marquis Hotel in Times Square, NY, NY. This year at NYSGE Fujifilm will highlight its latest technology featuring the recently launched ELUXEO®.
December 19, 2017
FUJIFILM Corporation (President: Kenji Sukeno) signed an agreement on December 19th for the investment of 470 million yen in EdiGene Corporation, a drug discovery startup, participating its series A round. As a result, Fujifilm will acquire 11.7% of EdiGene’s total shares. Along with this equity investment, the companies have signed a joint research agreement aimed at discovering gene therapy drugs1.
Allendale, N.J., December 6, 2017– As part of its ongoing commitment to promoting early detection of colon cancer, FUJIFILM Medical Systems U.S.A., Inc. - Endoscopy today announced its partnership with Fight Colorectal Cancer, the leading colorectal cancer advocacy organization. The two organizations will support a national movement called “One Million Strong” that brings together the strength of more than one million colorectal cancer survivors living in the United States.
STAMFORD, Conn., November 26, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of enterprise imaging and medical informatics solutions, today announces the expansion of Fujifilm’s artificial intelligenc
STAMFORD, Conn., November 20, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leadin
STAMFORD, Conn., November 20, 2017 – FUJIFILM Medical Systems U.S.A., Inc
Fujifilm debuts the new FDR Go PLUS version and announces installations of the FDR AQRO mini mobile digital radiography solution
STAMFORD, Conn., November 21, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leadin
Stamford, CT, November 21, 2017 (Booth #4111, South Hall) – FUJIFILM Medical Systems U.S.A., Inc.,
Stamford, CT, November 21, 2017 – FUJIFILM Medical Systems U.S.A., Inc.,
BOTHELL, WA, November 21, 2017 – FUJIFILM SonoSite Inc., spe
Stamford, CT, November 21, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic i
Billingham, United Kingdom, November 21, 2017 – FUJIFILM Diosynth Biotechnologies, a leading global Contract Development and Manufacturing Organization (CDMO), is pleased to announce that its Chief Executive Officer, Steve Bagshaw, has been awarded “North East Business Executive of the Year 2017”; a prestigious award organized by The Journal in Newcastle, U.K.
Acquiring new transgenic technology applicable to iPS cell production
Concludes Partnership Agreement for Contract Development and Manufacturing of Regenerative Medicine Products
Designation recognizes products that bring improvements to the health care industry
Company accelerates investment of approximately 3.2 billion yen for boosting CDMO capacity
November 6, 2017
BOTHELL, WA., October 27, 2017 (Booth #2307) – FUJIFILM SonoSite, Inc., specialists in developing cutting-edge ultrasound solutions and providing world-leading education to enable point-of-care visuali
BOTHELL, WA., October 27, 2017 (Booth #405) – FUJIFILM SonoSite, Inc., specialists in developing cutting-edge ultrasound solutions and providing world-leading education to enable point-of-care visualiz
Wayne, N.J.
Wayne, NJ, October 12, 2017 – FUJIFILM Medical Systems U.S.A. Inc.,- Endoscopy today introduced ELUXEO™, a next-generation endoscopic video imaging system to its portfolio.
Wayne, N.J., October 12, 2017 (Booth #1201) – FUJIFILM Medical Systems U.S.A., Inc – Endoscopy will debut its new innovative video endoscopy system, ELUXEO™, at the Annual Scientific Meeting of the World Congress of Gastroenterology (WCOG) at the American College of Gastroenterology (ACG) on October 13-17, 2017 at the Orange County Convention
Stamford, CT, October 6, 2017— The Health Management Academy (The Academy), a network comprised entirely of executive members from the country's largest integrated health systems, recently featured two FUJIFILM Medical System’s U.S.A., Inc.
Madison, Wisconsin, September 20, 2017— Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of differentiated cells derived from human induced pluripotent stem cells (iPSCs), and Nanion Technologies GmbH (Nanion
Stamford, CT, September 18, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging solutions with a comprehensive portfolio of digital radiography (DR) and mammography solutions, today a
MADISON, WIS., September 13, 2017 – Cellular Dynamics International (CDI), a FUJIFILM company, today announced that it will host the iForumSM 2017 meetings at The Buck Institute (Novato, CA) on September 14, 2017, Ha
Teesside, U.K., September 12, 2017 – FUJIFILM Diosynth Biotechnologies, a leading Contract Development and Manufacturing Organization (CDMO) with experience focused on the development and manufacture of recombinant biopharmaceuticals and advanced therapies, has announced its opening of the 10,000 square foot, state-of-the-art cell culture Process Development Laboratories in Wilton Centre, Teesside.
Stamford, CT, September 6, 2017–FUJIFILM Medical Systems U.S.A., Inc., a leading provider of medical informatics solutions, introduces support for DICO
Clinical Development of Liposome Drug for Improvement of Pharmacological Efficacy through Selective Delivery of Anti-Cancer Agent to Tumors
Company’s solutions to play key role in MHS Genesis project
Stamford, CT, August 21, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of Enterprise Imaging and medical informatics solutions, today announced it achieved a business milestone as the Enterprise Imag
August 8, 2017
FUJIFILM Corporation (President: Kenji Sukeno) announced the commencement of a Phase I clinical trial of its anti-cancer drug FF-10101 in the Unites States in patients with relapsed or refractory acute myeloid leukemia (AML).
Stamford, CT, August 3, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of medical informatics and diagnostic imaging products, announced the release of its Synapse PACS version 5 in the United States. Featuring the latest server-side rendering architecture, Synapse 5 is one component of Fujifilm’s comprehensive enterprise imaging portfolio which includes Synapse VNA, Enterprise Viewer, Cardiovascular, 3D, RIS and cloud services.
Stamford, CT, August 3, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of medical informatics and diagnostic imaging products, announced the release of its Synapse PACS version 5 in the United States. Featuring the latest server-side rendering architecture, Synapse 5 is one component of Fujifilm’s comprehensive enterprise imaging portfolio which includes Synapse VNA, Enterprise Viewer, Cardiovascular, 3D, RIS and cloud services.
Stamford, CT, July 31, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, today announced that The Mammography Center of Monterey, an ACR-accredited breast imaging center based in Monterey, CA, has installed Fujifilm’s ASPIRE Cristalle FFDM system with Digital Breast Tomosynthesis (DBT). The innovative 3D breast imaging technology has been in use at the center since April.
Wayne, N.J., July 31, 2017 – FUJIFILM Medical Systems U.S.A., Inc. today announced the launch of two new additions to its advanced endoscopic platform including ClutchCutter and FlushKnife devices. Designed for use with compatible endoscopes, these devices aid clinicians in performing effective endoscopic submucosal dissection (ESD) interventions within the digestive tract.
Healthcare business expanded from medical imaging to include biopharmaceuticals and regenerative medicine.
BEND, OR (July 12, 2017) — The Center Orthopedic & Neurosurgical Care & Research recently purchased new digital x-ray equipment that allows lower radiation and simplified image acquisition. They are the first organization in the Pacific Northwest to install Fujifilm’s FDR D-EVO GL for long length imaging. At 49” tall, this equipment captures an entire long length image in a single exposure instead of multiple images and exposures that would be stitched together with software.
Stamford, CT, June 28, 2017 (Booth #221) – FUJIFILM Medical Systems U.S.A., Inc., will present its comprehensive portfolio of digital radiography and mammography solutions designed to optimize workflow and increase the safety and satisfaction of patients at the American Healthcare Radiology Administrators (AHRA) 2017 Annual Meeting. The event, which is a premier educational event for radiology administration, will occur on July 9-12, 2017 at the Anaheim Convention Center in Anaheim, California.
Billingham, United Kingdom, June 20, 2017 ‒ FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system which was introduced to the market during the BIO 2007 convention in Boston, Massachusetts.
Stamford, CT, June 19, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, today announced that its Synapse PACS line has been granted Authority to Operate (ATO) on networks in the U.S. Department of Defense (DoD), making Fujifilm the first vendor with a networked medical system to attain a Risk Management Framework (RFM)-based ATO.
Wayne, N.J., May 10, 2017 (Booth #143)– The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. will display its latest imaging product innovations in pulmonology at the annual meeting of the American Thoracic Society (ATS) on May 21 – 23, 2017 in Washington, D.C.
MADISON, WIS, May 8, 2017 – Opsis Therapeutics ('Opsis'), a company developing treatments for retinal diseases, today announced the formation of its scientific advisory board (SAB). Approved by the executive leadership team, the SAB is established to advise on the development and advancement to the clinic of the Opsis pipeline of first-in-class retinal cell therapies.
Wayne, N.J., May 2, 2017 (Booth #2232)– The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. will showcase its latest innovations in endoscopic imaging technologies and solutions at Digestive Disease Week (DDW). The conference which takes place May 7-9, 2017 in Chicago, IL is the largest gathering of physicians, researchers and academics in the fields of gastroenterology, endoscopy and gastrointestinal surgery.
Wayne, N.J., May 2, 2017 (Booth #329)– The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. will showcase its latest innovations in endoscopic imaging technologies and solutions at the Society of Gastroenterology Nurses and Associates (SGNA) 44th Annual Course. The annual gathering, which attracts nearly 2,000 professionals in the gastroenterology field, will occur May 7-9, 2017 in New Orleans, Louisiana.
Madison, Wisconsin, April 19, 2017— Cellular Dynamics International (CDI), a FUJIFILM company and a leading developer and manufacturer of induced pluripotent stem cells (iPS), today announced it has signed a collaboration agreement with the Harvard Stem Cell Institute (HSCI), a novel network of stem cell scientists that extends from the University to its affiliated hospitals and the biomedical industry.
Stamford, CT, February 1, 2017 (Booth #551) – FUJIFILM Medical Systems U.S.A., Inc., and FUJIFILM SonoSite, Inc. will present its comprehensive Synapse Enterprise Imaging product portfolio and its SonoSite iViz solution which integrates ultrasound with medical IT at the Healthcare Information and Management Systems Society (HIMSS) conference and exhibition held February 19-23, 2017 at Orange County Convention Center in Orlando, Florida.
Stamford, CT, January 23, 2017 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, today announced that its Digital Breast Tomosynthesis (DBT), as an optional software upgrade for its ASPIRE Cristalle digital mammography system, has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA). The optional DBT upgrade for the ASPIRE Cristalle system is now available in the United States.
Stamford, CT, January 18, 2017 – FUJIFILM Medical Systems U.S.A., Inc. has now formed a strategic alliance with Renovo Solutions to offer Technology Management Solutions which consist of multi-vendor service (MVS) options for the maintenance and management of medical imaging and biomedical equipment. The new alliance is the result of growing demand from valued Fujifilm customers seeking to gain the benefits of a single supplier MVS relationship.
Wayne, N.J., January 12, 2017 (Booth #953) – The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc., will feature its latest portfolio of endoscopic imaging products at the 53rd Society of Thoracic Surgeons (STS) Annual Meeting, held from January 21 to January 25 in Houston, Texas.
Toronto, Canada, January 12, 2017 – FUJIFILM VisualSonics Inc., a world leader in high-frequency ultrasound imaging systems and subsidiary of FUJIFILM SonoSite, Inc., today announced clearance from Health Canada for its Vevo® MD, the world’s first Ultra High-Frequency (UHF) clinical ultrasound system. The Vevo MD uniquely operates at much higher frequencies than any conventional ultrasound system currently available.
Stamford, CT, November 22, 2016 (Booth #6713, North Building, Hall B) – The TeraMedica Division of FUJIFILM Medical Systems U.S.A., Inc., a leading provider of medical informatics solutions, announced the release of Synapse VNA version 6.2, the next generation of its enterprise-wide medical information and image management solution at the Radiological Society of North America 2016 conference and exhibition. RSNA 2016 is held November 27 – December 2, 2016 at McCormick Center in Chicago, Illinois.
Stamford, CT, November 22, 2016 (Booth #6713, North Building, Hall B) – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, will showcase its evolving Enterprise Imaging portfolio of Synapse integrated solutions and spotlight enhanced features and next generation upgrades at the Radiological Society of North America 2016 conference and exhibition held November 27 – December 2, 2016 at McCormick Center in Chicago, Illinois.
New FDR AQRO1 compact mobile DR debuts; FDR Go offers updated features.
Stamford, CT, November 22, 2016 (Booth #6713, North Building, Hall B) –FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, will present the next generation of its cutting edge image processing technology, Dynamic Visualization II at the annual meeting of the Radiological Society of North America (RSNA), from November 27 – December 2, 2016 at McCormick Center in Chicago, Illinois.
Stamford, CT, November 22, 2016 (Booth #6713, North Building, Hall B) –FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, will demonstrate the FDR D-EVO GL detector at the 2016 annual meeting of the Radiological Society of North America (RSNA), held November 27-December 2 at McCormick Place in Chicago, Illinois.
Company sponsors two RSNA educational sessions; hosts In-Booth Healthcare Theater; showcases comprehensive product portfolio
Stamford, CT, November 1, 2016 – The TeraMedica Division of FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products and medical informatics solutions, today announced an important business milestone in serving global healthcare providers. The company’s Synapse VNA, an enterprise-wide medical information and image management solution, now manages nearly 10 billion objects – data and images – via 350 installations serving more than 1000 facilities worldwide.
Billingham, United Kingdom, RTP, North Carolina and College Station, Texas, U.S.A., March 1 2017‒ FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced the expansion of its Monoclonal Antibody development and manufacturing services with the introduction of its Saturn mAb Platform™.
